CircNova key facts
- Operator of a biotechnology company intended to focus on non-coding RNA with many mechanisms of action against undruggable disease targets.
- It has raised $3.3M across 1 recorded rounds; the latest was Seed Round ($3.3M) in Feb 2025.
- Notable investors include US National Science Foundation, Spark Capital, Service Provider Capital, Michigan Rise, Douglas Song — 10 tracked in total.
- Status: Privately Held (backing).
- ·Watch CircNova: the Monday email on marks, rounds and moves
CircNova funding rounds
1 roundsHow much has CircNova raised?
CircNova has raised $3.3 million across 1 recorded round since 2025. The largest was a $3.3 million seed round in Feb 2025.
CircNova investors
10 investors are on record for CircNova, including US National Science Foundation, Spark Capital, Service Provider Capital and Michigan Rise. The seed round in Feb 2025 drew 7 investors.
About CircNova
Operator of a biotechnology company intended to focus on non-coding RNA with many mechanisms of action against undruggable disease targets. The company uses artificial intelligence to generate, analyze, and identify circular RNA for therapeutic development, enabling biopharmaceutical companies to develop treatments for undruggable diseases, improve patient outcomes, and address major unmet clinical needs.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Detroit, MI, United States
- Founded
- 2023
- Employees
- 9
- Website
- circnova.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
CircNova doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.